Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|April 17, 2008
USP helping FDA with testing for heparin contamination
The Food & Drug Administration has asked the United States Pharmacopeia to develop more sensitive tests to detect contamination in heparin products.
Advertisement
New heparin monographs should be coming from the
Advertisement
Related to this article
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
Mark Garofoli, PharmD, BCGP, CPE, CTTS, explains how to guide patients past crowded combination products, uncertain decongestants, and hidden risks in OTC aisles.
Chad Worz, PharmD, BCGP, FASCP, explains why the Main Street Pharmacy Access Act's reimbursement provisions are key to unlocking pharmacy's clinical future.
Cohort studies found no clear cardiovascular benefit from PPV23 vaccination, leaving its role in cardiovascular prevention unresolved.
A high-dose flu vaccine lowered flu- and pneumonia-related hospital stays in patients with chronic lung disease, reinforcing flu and pneumococcal vaccinations.
In a review of records assessing patients with type 2 diabetes, researchers provide a comprehensive detail of strategies leading to diabetes remission though gaps persist.
A guide built from conversations with pharmacists on social media and independent pharmacy owners.
Advertisement
Advertisement
Trending on Drug Topics
1
GLP-1 Therapy Must Prioritize Metabolic Quality Over Weight Loss
2
COVID-19 Vaccine Hesitancy in 2026: How Attitudes Have Shifted
3
Social Media Best Practices for Pharmacists: Why Visibility Matters
4
High-Dose Vaccines Reduce Hospital Stays in Older Adults With Lung Disease
5